Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026
Key Highlights
- ➤Tango (TNGX) will present updated vopimetostat combination data at ESMO Congress 2026
- ➤Phase 1/2 study covers MTAPdel/RASmut metastatic PDAC and NSCLC patients
- ➤Vopimetostat is being evaluated with daraxonrasib or zoldonrasib
- ➤PDAC-focused investor webcast scheduled for October 23 at 7:30 am ET
BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026, which will be held October 23-27, 2026 in Madrid, Spain.
Abstracts will be available on the ESMO website on Monday, October 19, 2026,12:05 am CEST. The data cutoff in the abstract is as of April 3, 2026. The poster presentation will include updated data.
Get started
Create a free account to read the full story.